Thyroid status as a prognostic factor in oncology
https://doi.org/10.18027/2224-5057-2015-2-13-20
Abstract
Acting via a cell surface receptor on integrin v 3, thyroid hormone is pro-angiogenic and pro-proliferating. Nongenomic mechanisms of actions of the thyroid hormones at v 3 include modulation of activities of intracellular messengers: mitogen-activated protein kinase and phosphatidyl inositol-3-kinase. Thyroid hormone may increase activity of factors that support neovascularization, cell motility and cell proliferation. There are clinical and epidemiological dates about impact induced hypothyroidism on the disease and survival in cancer patients in this review
About the Authors
Ruslan Ivanovich Glushakov
S. M. Kirov Military Medical Academy
Russian Federation
Ph.D., the department of obstetrics and gynecology
Russian Federation
Ph.D., the department of obstetrics and gynecology
OLGA VLAS’EVA
ФГБВОУ ВПО «Военно-медицинская академия им. С. М. Кирова» МО РФ,
Russian Federation
врач-онколог клиники акушерства и гинекологии, Санкт-Петербург
Russian Federation
врач-онколог клиники акушерства и гинекологии, Санкт-Петербург
IVAN SOBOLEV
ГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)»
Russian Federation
врач-онколог онкогинекологического отделения , Санкт-Петербург
Russian Federation
врач-онколог онкогинекологического отделения , Санкт-Петербург
SERGEJ PROSHIN
ГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РФ
Russian Federation
д. м.н., заведующий кафедрой фармакологии, Санкт-Петербург
Russian Federation
д. м.н., заведующий кафедрой фармакологии, Санкт-Петербург
NATALYA TAPIL’SKAYA
ГБОУ ВПО «Санкт-Петербургс
Russian Federation
д. м.н., профессор кафедры онкологии и кафедры акушерства и гинекологии
Russian Federation
д. м.н., профессор кафедры онкологии и кафедры акушерства и гинекологии
References
1. Aghajanova L., Lindeberg M., Carlson I. B. et al. Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue // Reprod. Biomed. Online. 2009; 18 (3): 337–347.
2. Ashur-Fabian O., Blumenthal D. T., Bakon M. et al. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature // Anticancer Drugs. 2013; 24 (3): 315–23.
3. Balkwill F., Charles K. A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease // Cancer Cell. 2005; 7: 211–217.
4. Billon N., Terrinoni A., Jolicoeur C. et al. Roles for p53 and p73 during oligodendrocyte development // Development. 2004; 131: 1211–20.
5. Brown R. L. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management // Target Oncol. 2011; 6 (4): 217–26.
6. Cao X., Kambe F., Moeller L. C. et al. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts // Mol. Endocrinol. 2005; 19 (1):
7. 102–112.
8. Carvalho A. F., Dimellis D., Gonda X. et al. Rapid cycling in bipolar disorder: a systematic review // J Clin Psychiatry. 2014; 75 (6): e578–86.
9. Cohen K., Ellis M., Khoury S. et al. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via v 3 integrin // Mol. Cancer Res. 2011; 9 (10): 1385–94.
10. Crile G. Jr. The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth // Cancer. 1957; 10 (6): 1119–37.
11. Davis F. B., Tang H. Y., Shih A. et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells // Cancer Res. 2006; 66 (14): 7270–7275.
12. Davis F. B., Mousa S. A., O’Connor L. et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface // Circ. Res. 2004; 94 (11): 1500–1506.
13. Davis P. J., Lin H. Y., Tang H. Y. et al. Adjunctive input to the nuclear thyroid hormone receptor from the cell surface receptor for the hormone // Thyroid. 2013; 23 (12): 1503–9.
14. Demartini B., Ranieri R., Masu A. et al. Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism: a cross-sectional study // J Nerv Ment Dis. 2014; 202 (8): 603–7.
15. Faber J, Selmer C. Cardiovascular disease and thyroid function // Front Horm Res. 2014; 43: 45–56.
16. Farwell A. P., Dubord–Tomasetti S.A., Pietrzykowski A. Z., Leonard J. L. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3»,5’-triiodothyronine // Brain Res. Dev. Brain Res. 2005; 154 (11): 121–135.
17. Hercbergs A. A., Suh J. H., Lee S. et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study // Anticancer Res. 2003; 23 (1B): 617–626.
18. Huang S. A. Physiology and pathophysiology of type 3 deiodinase in humans // Thyroid. – 2005; 15 (8): 875–881.
19. Humphrey L. J., Swerdlow M. The relationship of breast disease to thyroid disease // Cancer. 1964; 17: 1170–3.
20. Linetsky E., Hercbergs A. A., Dotan S. et al. Time to tumor progression (TTP) and quality of life (QOL) following propylthiouracil induction of chemical hypothyroidism in failed malignant gliomas // Abstracts from the World Federation of
21. Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology: Edinburgh, U.K. 2005: 318.
22. Lodish M. B., Stratakis C. A. Endocrine side effects of broad-acting kinase inhibitors // Endocr Relat Cancer. 2010; 17 (3): R233–44.
23. Moeller L. C., Dumitrescu A. M., Walker R. L. et al. Thyroid hormone responsive genes in cultured human fibroblasts // J. Clin. Endocrinol. Metab. 2005: 90 (2): 936–943.
24. Nelson M., Hercbergs A., Rybicki L., Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer // Arch Otolaryngol Head Neck Surg. 2006; 132 (10): 1041–6.
25. Rae M. T., Gubbay O., Kostogiannou A. et al. Thyroid hormone signaling in human ovarian surface epithelial cells // J. Clin. Endocrinol. Metab. 2007.; 92 (1): 322–327.
26. Reid I., Sharpe I., McDevitt J. et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha // Br J Cancer. 1991; 64 (5): 915–8.
27. Riesenbeck L. M., Bierer S., Hoffmeister I. et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib // World J Urol. 2011; 29 (6): 807–13.
28. Russfield A. B. Histology of the human hypophysis in thyroid disease-hypothyroidism, hyperthyroidism, and cancer // J Clin Endocrinol Metab. 1955; 15 (11): 1393–408.
29. Sabatier R., Eymard J. C., Walz J. et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? // Ann Oncol. 2012; 23 (3): 714–21.
30. Schmidinger M., Vogl U. M., Bojic M. et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? // Cancer. 2011; 117 (3): 534–44.
31. Schwartz M. A. Integrin signaling revisited // Trends Cell Biol. 2001; 11: 466– 470.
32. Shih C., Chen S., Yen C. et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins // Endocrinology. 2004; 145: 2804–2814.
33. Siegrist-Kaiser C.A., Juge-Aubry C., Tranter M. P. et al. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel extranuclear action of thyroid hormone // J. Biol. Chem. 1990; 265: 5296–5302.
34. Smith T. G., Roblins P. A., Ratelife P. J. The human side of hypoxia-inducible factor // Brit. J. Haemot. 2008; 141: 325–334.
35. Tang H. Y., Lin H. Y., Zhang S. et al. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor // Endocrinology. 2004; 145: 3265–3272.
36. Viguerie N., Millet L., Avizou S. et al. Regulation of human adipocyte gene expression by thyroid hormone // J. Clin. Endocrinol. Metab. 2002; 87: 630–634.
37. Wang X., Page-McCaw A. A matrix metalloproteinase mediates long-distance attenuation of stem cell proliferation // J Cell Biol. 2014; 206 (7): 923–36.
38. Weijl N. I., Van der Harst D., Brand A. et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment // J Clin Oncol. 1993; 11 (7): 1376–83.
39. Wolter P., Stefan C., Decallonne B. et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) // ASCO Meeting Abstracts 5126, 2008.
Review
For citations:
Glushakov R.I., VLAS’EVA O., SOBOLEV I., PROSHIN S., TAPIL’SKAYA N. Thyroid status as a prognostic factor in oncology. Malignant tumours. 2015;(2):13-20. (In Russ.) https://doi.org/10.18027/2224-5057-2015-2-13-20
Views:
1421
Email this article 